TGF-beta signal transduction in chronic kidney disease

Frontiers in Bioscience

Volumn 14, Issue 7, 2009, Pages 2448-2465

  Schnaper, H William ^a,b   Jandeska, Sara ^c   Runyan, Constance E ^a,b   Hubchak, Susan C ^a,b   Basu, Rajit K ^a,b   Curley, Jessica F ^a,b   Smith, Ronald D ^a,b   Hayashida, Tomoko ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Children's Memorial Research Center   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cross talk; Fibrosis; Review; Signal transduction; Smad; TGF beta

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA;

CHRONIC KIDNEY FAILURE; HUMAN; KIDNEY; METABOLISM; PATHOPHYSIOLOGY; PROTEIN BINDING; REVIEW; SIGNAL TRANSDUCTION;

HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; PROTEIN BINDING; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 63849233538     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3389     Document Type: Article

References (201)

1. N. L. Thompson, K. C. Flanders, J. M. Smith, L. R. Ellingsworth, A. B. Roberts and M. B. Sporn: Expression of transforming growth factor-beta 1 in specific cells and tissues of adult and neonatal mice. J Cell Biol, 108 (2), 661-9 (1989). (Pubitemid 19065861)
2. M. Kitamura, T. Suto, T. Yokoo, F. Shimizu and L. G. Fine: Transforming growth factor-beta 1 is the predominant paracrine inhibitor of macrophage cytokine synthesis produced by glomerular mesangial cells. J Immunol, 156 (8), 2964-71 (1996). (Pubitemid 126660645)
3. M. M. Shull, I. Ormsby, A. B. Kier, S. Pawlowski, R. J. Diebold, M. Yin, R. Allen, C. Sidman, G. Proetzel, D. Calvin and et al.: Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature, 359 (6397), 693-9 (1992).
4. T. S. Suto, L. G. Fine and M. Kitamura: Mesangial cellderived transforming growth factor-beta 1 reduces macrophage adhesiveness with consequent deactivation. Kidney Int, 50 (2), 445-52 (1996). (Pubitemid 26274371)
5. M. G. Alexandrow and H. L. Moses: Transforming growth factor beta and cell cycle regulation. Cancer Res, 55 (7), 1452-7 (1995).
6. D. S. Goumenos, S. Tsakas, A. M. El Nahas, S. Alexandri, S. Oldroyd, P. Kalliakmani and J. G. Vlachojannis: Transforming growth factor-beta (1) in the kidney and urine of patients with glomerular disease and proteinuria. Nephrol Dial Transplant, 17 (12), 2145-52 (2002). (Pubitemid 35446670)
7. K. Murakami, T. Takemura, S. Hino and K. Yoshioka: Urinary transforming growth factor-beta in patients with glomerular diseases. Pediatr Nephrol, 11 (3), 334-6 (1997). (Pubitemid 27230820)
8. R. P. Woroniecki, I. F. Shatat, K. Supe, Z. Du and F. J. Kaskel: Urinary cytokines and steroid responsiveness in idiopathic nephrotic syndrome of childhood. Am J Nephrol, 28 (1), 83-90 (2008). (Pubitemid 350126497)
9. A. M. Wasilewska and W. M. Zoch-Zwierz: Transforming growth factor-beta1 in nephrotic syndrome treated with cyclosporine and ACE inhibitors. Pediatr Nephrol, 19 (12), 1349-53 (2004). (Pubitemid 39530541)
10. J. H. Kim, B. K. Kim, K. C. Moon, H. K. Hong and H. S. Lee: Activation of the TGF-beta/Smad signaling pathway in focal segmental glomerulosclerosis. Kidney Int, 64 (5), 1715-21 (2003). (Pubitemid 37323700)
11. T. Yamamoto, N. Noble, D. E. Miller and W. A. Border: Sustained expression of TGF-beta1 underlies development of progressive kidney fibrosis. Kidney Int., 45, 916-927 (1994). (Pubitemid 24094509)
12. Y. Isaka, Y. Fujiwara, N. Ueda, Y. Kaneda, T. Kamada and E. Imai: Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or plateletderived growth factor gene into the rat kidney. J. Clin. Invest., 92, 2597-2601 (1993). (Pubitemid 24006522)
13. M. M. Mozes, E. P. Bottinger, T. A. Jacot and J. B. Kopp: Renal expression of fibrotic matrix proteins and of transforming growth factor-beta (TGF-beta) isoforms in TGF-beta transgenic mice. J Am Soc Nephrol, 10, 271- 280 (1999). (Pubitemid 29068066)
14. Y. Akagi, Y. Isaka, M. Arai, T. Kaneko, M. Takenaka, T. Moriyama, Y. Kaneda, A. Ando, Y. Orita, T. Kamada, N. Ueda and E. Imai: Inhibition of TGFbeta1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int., 50, 148- 155 (1996). (Pubitemid 26323708)
15. P. Lavoie, G. Robitaille, M. Agharazii, S. Ledbetter, M. Lebel and R. Lariviere: Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats. J Hypertens, 23 (10), 1895-903 (2005). (Pubitemid 41830430)
16. W. A. Border, N. A. Noble, T. Yamamoto, J. R. Harper, Y. Yamaguchi, M. D. Pierschbacher and E. Ruoslahti: Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature, 360 (6402), 361-4 (1992). (Pubitemid 23000677)
17. L. M. Russo, E. del Re, D. Brown and H. Y. Lin: Evidence for a role of transforming growth factor (TGF)- beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-beta type II receptor. Diabetes, 56 (2), 380-8 (2007).
18. A. B. Roberts, K. C. Flanders, U. I. Heine, S. Jakowlew, P. Kondaiah, S. J. Kim and M. B. Sporn: Transforming growth factor-beta: multifunctional regulator of differentiation and development. Philos Trans R Soc Lond B Biol Sci, 327 (1239), 145-54 (1990).
19. E. Piek, C.-H. Heldin and P. ten Dijke: Specificity, diversity and regulation in TGF-beta superfamily signaling. FASEB J, 13, 2105-2124 (1999).
20. Y. Shi and J. Massague: Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell, 113 (6), 685-700 (2003). (Pubitemid 36724933)
21. R. A. Randall, S. Germain, G. J. Inman, P. A. Bates and C. S. Hill: Different Smad2 partners bind a common hydrophobic pocket in Smad2 via a defined proline-rich motif. Embo J, 21 (1-2), 145-56 (2002). (Pubitemid 34087083)
22. A.-C. Poncelet, M. P. de Caestecker and H. W. Schnaper: The TGF-beta/SMAD signaling pathway is present and functional in human mesangial cells. Kidney Int., 56, 1354- 1365 (1999). (Pubitemid 29451243)
23. E. P. Bottinger and M. Bitzer: TGF-beta signaling in renal disease. J Am Soc Nephrol, 13 (10), 2600-10 (2002).
24. J. Cheng and J. P. Grande: Transforming growth factorbeta signal transduction and progressive renal disease. Exp Biol Med (Maywood), 227 (11), 943-56 (2002). (Pubitemid 36008302)
25. K. Sharma, F. N. Ziyadeh, B. Alzahabi, T. A. McGowan, S. Kapoor, B. R. Kurnik, P. B. Kurnik and L. S. Weisberg: Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes, 46, 854-859 (1997). (Pubitemid 27188264)
26. D. Koya, M. R. Jirousek, Y. W. Lin, H. Ishii, K. Kuboki and G. L. King: Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J. Clin. Invest., 100, 115-126 (1997). (Pubitemid 27311249)
27. J. Gaedeke, N. A. Noble and W. A. Border: Curcumin blocks multiple sites of the TGF-beta signaling cascade in renal cells. Kidney Int, 66 (1), 112-20 (2004). (Pubitemid 38870087)
28. J. S. Munger, X. Huang, H. Kawakatsu, M. J. Griffiths, S. L. Dalton, J. Wu, J. F. Pittet, N. Kaminski, C. Garat, M. A. Matthay, D. B. Rifkin and D. Sheppard: The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell, 96 (3), 319-28. (1999). (Pubitemid 29077586)
29. T. Hayashida and H. W. Schnaper: High ambient glucose enhances sensitivity to TGF-beta1 via extracellular signal-regulated kinase and protein kinase Cdelta activities in human mesangial cells. J Am Soc Nephrol, 15 (8), 2032- 41 (2004). (Pubitemid 39031342)
30. T. Hayashida, M. H. Wu, A. Pierce, A. C. Poncelet, J. Varga and H. W. Schnaper: MAP-kinase activity necessary for TGFbeta1-stimulated mesangial cell type I collagen expression requires adhesion-dependent phosphorylation of FAK tyrosine 397. J Cell Sci, 120 (Pt 23), 4230-40 (2007).
31. N. Yevdokimova, N. A. Wahab and R. M. Mason: Thrombospondin-1 is the key activator of TGF-beta1 in human mesangial cells exposed to high glucose. J Am Soc Nephrol, 12 (4), 703-12 (2001). (Pubitemid 32246698)
32. T. Nakagawa, H. Y. Lan, O. Glushakova, H. J. Zhu, D. H. Kang, G. F. Schreiner, E. P. Bottinger, R. J. Johnson and Y. Y. Sautin: Role of ERK1/2 and p38 mitogen-activated protein kinases in the regulation of thrombospondin-1 by TGF-beta1 in rat proximal tubular cells and mouse fibroblasts. J Am Soc Nephrol, 16 (4), 899-904 (2005). (Pubitemid 41710300)
33. Y. Zhou, M. H. Poczatek, K. H. Berecek and J. E. Murphy-Ullrich: Thrombospondin 1 mediates angiotensin II induction of TGF-beta activation by cardiac and renal cells under both high and low glucose conditions. Biochem Biophys Res Commun, 339 (2), 633-41 (2006). (Pubitemid 41739714)
34. N. A. Wahab, L. Schaefer, B. S. Weston, O. Yiannikouris, A. Wright, A. Babelova, R. Schaefer and R. M. Mason: Glomerular expression of thrombospondin-1, transforming growth factor beta and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli. Diabetologia, 48 (12), 2650-60 (2005). (Pubitemid 41738234)
35. L. Gao, W. Qiu, Y. Wang, W. Xu, J. Xu and J. Tong: Sublytic complement C5b-9 complexes induce thrombospondin-1 production in rat glomerular mesangial cells via PI3-k/Akt: association with activation of latent transforming growth factor-beta1. Clin Exp Immunol, 144 (2), 326-34 (2006).
36. C. Daniel, J. Wiede, H. C. Krutzsch, S. M. Ribeiro, D. D. Roberts, J. E. Murphy-Ullrich and C. Hugo: Thrombospondin-1 is a major activator of TGF-beta in fibrotic renal disease in the rat in vivo. Kidney Int, 65 (2), 459-68 (2004). (Pubitemid 38130640)
37. T. Ito, J. D. Williams, D. J. Fraser and A. O. Phillips: Hyaluronan regulates transforming growth factor-beta1 receptor compartmentalization. J Biol Chem, 279 (24), 25326-32 (2004). (Pubitemid 38756787)
38. G. M. Di Guglielmo, C. Le Roy, A. F. Goodfellow and J. L. Wrana: Distinct endocytic pathways regulate TGFbeta receptor signalling and turnover. Nat Cell Biol, 5 (5), 410-21 (2003). (Pubitemid 36592263)
39. M. J. Goumans, G. Valdimarsdottir, S. Itoh, F. Lebrin, J. Larsson, C. Mummery, S. Karlsson and P. ten Dijke: Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol Cell, 12 (4), 817-28 (2003). (Pubitemid 37352776)
40. F. Lebrin, M. J. Goumans, L. Jonker, R. L. Carvalho, G. Valdimarsdottir, M. Thorikay, C. Mummery, H. M. Arthur and P. ten Dijke: Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. Embo J, 23 (20), 4018-28 (2004). (Pubitemid 39472423)
41. C. S. Craft, D. Romero, C. P. Vary and R. C. Bergan: Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway. Oncogene, 26 (51), 7240-50 (2007). (Pubitemid 350085322)
42. D. Rotzer, M. Roth, M. Lutz, D. Lindemann, W. Sebald and P. Knaus: Type III TGF-beta receptor-independent signalling of TGF-beta2 via TbetaRII-B, an alternatively spliced TGF-beta type II receptor. Embo J, 20 (3), 480-90 (2001). (Pubitemid 32126983)
43. A. Taniguchi, K. Matsuzaki, K. Nakano, M. Kan and W. L. McKeehan: Ligand-dependent and -independent interactions with the transforming growth factor type II and I receptor subunits reside in the aminoterminal portion of the ectodomain of the type III subunit. In vitro Cell Dev Biol Anim, 34 (3), 232-8 (1998). (Pubitemid 29077076)
44. T. Watanabe, T. Yamamoto, N. Ikegaya, Y. Fujigaki, H. Suzuki, A. Togawa, H. Fukasawa, M. Nagase and A. Hishida: Transforming growth factor-beta receptors in self-limited vs. chronic progressive nephritis in rats. J Pathol, 198 (3), 397-406 (2002). (Pubitemid 35277391)
45. T. Yamamoto, T. Watanabe, N. Ikegaya, Y. Fujigaki, K. Matsui, H. Masaoka, M. Nagase and A. Hishida: Expression of types I, II, and III TGF-beta receptors in human glomerulonephritis. J Am Soc Nephrol, 9 (12), 2253-61 (1998). (Pubitemid 28543803)
46. P. Ten Dijke, M. J. Goumans and E. Pardali: Endoglin in angiogenesis and vascular diseases. Angiogenesis, 11 (1), 79- 89 (2008).
47. L. Diez-Marques, R. Ortega-Velazquez, C. Langa, A. Rodriguez-Barbero, J. M. Lopez-Novoa, S. Lamas and C. Bernabeu: Expression of endoglin in human mesangial cells: modulation of extracellular matrix synthesis. Biochim Biophys Acta, 1587 (1), 36-44 (2002). (Pubitemid 34493832)
48. O. Scherner, S. K. Meurer, L. Tihaa, A. M. Gressner and R. Weiskirchen: Endoglin differentially modulates antagonistic transforming growth factor-beta1 and BMP-7 signaling. J Biol Chem, 282 (19), 13934-43 (2007). (Pubitemid 47100463)
49. M. J. Goumans, G. Valdimarsdottir, S. Itoh, A. Rosendahl, P. Sideras and P. ten Dijke: Balancing theactivation state of the endothelium via two distinct TGFbeta type I receptors. Embo J, 21 (7), 1743-53 (2002). (Pubitemid 34614630)
50. W. Shi, C. Sun, B. He, W. Xiong, X. Shi, D. Yao and X. Cao: GADD34-PP1c recruited by Smad7 dephosphorylates TGFbeta type I receptor. J Cell Biol, 164 (2), 291-300 (2004). (Pubitemid 38133948)
51. G. Valdimarsdottir, M. J. Goumans, F. Itoh, S. Itoh, C. H. Heldin and P. ten Dijke: Smad7 and protein phosphatase 1alpha are critical determinants in the duration of TGFbeta/ALK1 signaling in endothelial cells. BMC Cell Biol, 7, 16 (2006).
52. S. Hayes, A. Chawla and S. Corvera: TGFbeta receptor internalization into EEA1-enriched early endosomes: role in signaling to Smad2. J. Cell Biol., 158 (7), 1239-1249 (2002).
53. S. G. Penheiter, H. Mitchell, N. Garamszegi, M. Edens, J. J. E. Dore and E. B. Leof: Internalization-dependent and -independent requirements for transforming growth factor beta receptor signaling via the Smad pathway. Mol. Cell Biol., 22 (13), 4750-4759 (2002). (Pubitemid 34620410)
54. C. E. Runyan, H. W. Schnaper and A. C. Poncelet: The role of internalization in transforming growth factor beta1- induced Smad2 association with Smad anchor for receptor activation (SARA) and Smad2-dependent signaling in human mesangial cells. J Biol Chem, 280 (9), 8300-8 (2005). (Pubitemid 40349732)
55. D. Goto, H. Nakajima, Y. Mori, K. Kurasawa, N. Kitamura and I. Iwamoto: Interaction between Smad anchor for receptor activation and Smad3 is not essential for TGF-beta/Smad3-mediated signaling. Biochem. Biophys. Res. Commun., 281 (5), 1100-5 (2001). (Pubitemid 32924533)
56. Z. Lu, J. T. Murray, W. Luo, H. Li, X. Wu, H. Xu, J. M. Backer and Y. G. Chen: Transforming growth factor beta activates Smad2 in the absence of receptor endocytosis. J. Biol. Chem., 277 (33), 29363-29368 (2002). (Pubitemid 41079219)
57. Y. Zhou, S. Scolavino, S. F. Funderburk, L. F. Ficociello, X. Zhang and A. Klibanski: Receptor internalization-independent activation of Smad2 in activin signaling. Mol. Endocrinol., 18 (7), 1818-1826 (2004). (Pubitemid 38859587)
58. K. Arora and R. Warrior: A new Smurf in the village. Dev Cell, 1 (4), 441-2 (2001).
59. F. Y. Liu, X. Z. Li, Y. M. Peng, H. Liu and Y. H. Liu: Arkadia-Smad7-mediated positive regulation of TGF-beta signaling in a rat model of tubulointerstitial fibrosis. Am J Nephrol, 27 (2), 176-83 (2007). (Pubitemid 46588184)
60. A. C. Poncelet, H. W. Schnaper, R. Tan, Y. Liu and C. E. Runyan: Cell phenotype-specific down-regulation of Smad3 involves decreased gene activation as well as protein degradation. J Biol Chem, 282 (21), 15534-40 (2007). (Pubitemid 47093313)
61. W. Wang, V. Koka and H. Y. Lan: Transforming growth factor-beta and Smad signalling in kidney diseases. Nephrology (Carlton), 10 (1), 48-56 (2005). (Pubitemid 40349406)
62. A. B. Roberts, A. Russo, A. Felici and K. C. Flanders: Smad3: a key player in pathogenic mechanisms dependent on TGF-beta. Ann NY Acad Sci., 995, 1-10 (2003). (Pubitemid 36706609)
63. M. Uemura, E. S. Swenson, M. D. Gaca, F. J. Giordano, M. Reiss and R. G. Wells: Smad2 and Smad3 play different roles in hepatic stellate cell function and (alpha)-smooth muscle actin organization. Mol Biol Cell, 16 (9), 4214-24 (2005). (Pubitemid 41262890)
64. A. C. Poncelet and H. W. Schnaper: Sp1 and Smad proteins cooperate to mediate transforming growth factorbeta 1-induced alpha 2 (I) collagen expression in human glomerular mesangial cells. J Biol Chem, 276 (10), 6983-92 (2001). (Pubitemid 37391993)
65. M. K. Phanish, N. A. Wahab, P. Colville-Nash, B. M. Hendry and M. E. Dockrell: The differential role of Smad2 and Smad3 in the regulation of pro-fibrotic TGFbeta1 responses in human proximal-tubule epithelial cells. Biochem J, 393 (Pt 2), 601-7 (2006). (Pubitemid 43099100)
66. K. H. Wrighton, D. Willis, J. Long, F. Liu, X. Lin and X. H. Feng: Small C-terminal domain phosphatases dephosphorylate the regulatory linker regions of Smad2 and Smad3 to enhance transforming growth factor-beta signaling. J Biol Chem, 281 (50), 38365-75 (2006). (Pubitemid 46041960)
67. J. Massague: Integration of Smad and MAPK pathways: a link and a linker revisited. Genes Dev, 17 (24), 2993-7 (2003). (Pubitemid 38040762)
68. C. E. Pierreux, F. J. Nicolas and C. S. Hill: Transforming growth factor beta-independent shuttling of Smad4 between the cytoplasm and nucleus. Mol Cell Biol, 20 (23), 9041-54 (2000). (Pubitemid 32245933)
69. Y. Q. Xiao, K. Malcolm, G. S. Worthen, S. Gardai, W. P. Schiemann, V. A. Fadok, D. L. Bratton and P. M. Henson: Cross-talk between ERK and p38 MAPK mediates selective suppression of pro-inflammatory cytokines by transforming growth factor-beta. J Biol Chem, 277 (17), 14884-93 (2002). (Pubitemid 34952562)
70. L. Xu: Regulation of Smad activities. Biochim Biophys Acta, 1759 (11-12), 503-13 (2006). (Pubitemid 46054233)
71. G. J. Inman: Linking Smads and transcriptional activation. Biochem J, 386 (Pt 1), e1-e3 (2005).
72. R. A. Rahimi and E. B. Leof: TGF-beta signaling: A tale of two responses. J Cell Biochem (2007).
73. S. Mori, K. Matsuzaki, K. Yoshida, F. Furukawa, Y. Tahashi, H. Yamagata, G. Sekimoto, T. Seki, H. Matsui, M. Nishizawa, J. Fujisawa and K. Okazaki: TGF-beta and HGF transmit the signals through JNK-dependent Smad2/ 3phosphorylation at the linker regions. Oncogene, 23 (44), 7416-29 (2004). (Pubitemid 39382144)
74. M. C. Wilkes and E. B. Leof: Transforming growth factor beta activation of c-Abl is independent of receptor internalization and regulated by phosphatidylinositol 3- kinase and PAK2 in mesenchymal cultures. J Biol Chem, 281 (38), 27846-54 (2006). (Pubitemid 44414496)
75. T. Hayashida, M. P. de Caestecker and H. W. Schnaper: Cross-talk between ERK MAP kinase and Smadsignaling pathways enhances TGF-beta-dependent responses in human mesangial cells. FASEB J, 17, 1576-78 (2003).
76. T. Hayashida, A.-C. Poncelet, S. C. Hubchak and H. W. Schnaper: TGF-beta1 activates MAP kinases in human mesangial cells: a possible role in collagen expression. Kidney Int., 56, 1710-20 (1999). (Pubitemid 29518171)
77. X. Lin, X. Duan, Y. Y. Liang, Y. Su, K. H. Wrighton, J. Long, M. Hu, C. M. Davis, J. Wang, F. C. Brunicardi, Y. Shi, Y. G. Chen, A. Meng and X. H. Feng: PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling. Cell, 125 (5), 915-28 (2006). (Pubitemid 43795197)
78. G. Sapkota, M. Knockaert, C. Alarcon, E. Montalvo, A. H. Brivanlou and J. Massague: Dephosphorylation of the linker regions of Smad1 and Smad2/3 by small C-terminal domain phosphatases has distinct outcomes for bone morphogenetic protein and transforming growth factor-beta pathways. J Biol Chem, 281 (52), 40412-9 (2006). (Pubitemid 46041844)
79. K. Rombouts, T. Niki, P. Greenwel, A. Vandermonde, A. Wielant, K. Hellemans, P. De Bleser, M. Yoshida, D. Schuppan, M. Rojkind and A. Geerts: Trichostatin A, a histone deacetylase inhibitor, suppresses collagen synthesis and prevents TGF-beta (1)-induced fibrogenesis in skin fibroblasts. Exp Cell Res, 278 (2), 184-97 (2002). (Pubitemid 35002103)
80. L. C. Huber, J. H. Distler, F. Moritz, H. Hemmatazad, T. Hauser, B. A. Michel, R. E. Gay, M. Matucci-Cerinic, S. Gay, O. Distler and A. Jungel: Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. Arthritis Rheum, 56 (8), 2755-64 (2007). (Pubitemid 47237295)
81. M. Simonsson, C. H. Heldin, J. Ericsson and E. Gronroos: The balance between acetylation and deacetylation controls Smad7 stability. J Biol Chem, 280 (23), 21797-803 (2005). (Pubitemid 40827829)
82. C. E. Runyan, A. C. Poncelet and H. W. Schnaper: TGFbeta receptor-binding proteins: Complex interactions. Cell Signal 18, 2044-88 (2006).
83. T. Tsukazaki, T. A. Chiang, A. F. Davison, L. Attisano and J. L. Wrana: SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell, 95, 779-91 (1998). (Pubitemid 29014458)
84. G. Wu, Y. Chen, B. Ozdamar, C. A. Gyuricza, A. Chong, J. L. Wrana, J. Massague and Y. Shi: Structural basis of Smad2 recognition by the Smad anchor for receptor activation. Science, 287, 92-7 (2000). (Pubitemid 30033225)
85. B. A. Hocevar, A. Smine, X. X. Xu and P. H. Howe: The adaptor molecule Disabled-2 links the transforming growth factor beta receptors to the Smad pathway. EMBO J., 20, 2789-2801 (2001). (Pubitemid 32938562)
86. A. V. Oleinikov, J. Zhao and S. P. Makker: Cytosolic adaptor protein Dab2 is an intracellular ligand of endocytic receptor gp600/megalin. Biochem J, 347 Pt 3, 613-21 (2000). (Pubitemid 30260949)
87. S. M. Morris, M. D. Tallquist, C. O. Rock and J. A. Cooper: Dual roles for the Dab2 adaptor protein in embryonic development and kidney transport. Embo J, 21 (7), 1555-64 (2002). (Pubitemid 34614612)
88. B. A. Hocevar, C. Prunier and P. H. Howe: Disabled-2 (Dab2) mediates transforming growth factor beta (TGFbeta)-stimulated fibronectin synthesis through TGFbeta-activated kinase 1 and activation of the JNK pathway. J Biol Chem, 280 (27), 25920-7 (2005). (Pubitemid 40962305)
89. R. Diwakar, A. L. Pearson, P. Colville-Nash, D. L. Baines and M. E. Dockrell: Role played by Disabled-2 in albumin induced MAP Kinase signalling. Biochem Biophys Res Commun (2007).
90. S. Ikeda, M. Kishida, Y. Matsuura, H. Usui and A. Kikuchi: GSK-3beta-dependent phosphorylation of adenomatous polyposis coli gene product can be modulated by beta-catenin and protein phosphatase 2A complexed with Axin. Oncogene, 19 (4), 537-45 (2000). (Pubitemid 30099367)
91. A. Kikuchi: Modulation of Wnt signaling by Axin and Axil. Cytokine Growth Factor Rev., 10 ( (3-4)), 255-65 (1999). (Pubitemid 30041403)
92. S. Kishida, H. Yamamoto, S. Hino, S. Ikeda, M. Kishida and A. Kikuchi: DIX domains of Dvl and axin are necessary for protein interactions and their ability to regulate beta-catenin stability. Mol Cell Biol, 19 (6), 4414- 22 (1999). (Pubitemid 29242015)
93. M. Furuhashi, K. Yagi, H. Yamamoto, Y. Furukawa, S. Shimida, Y. Nakamura, A. Kikuchi and K. Miyazono: Axin facilitates Smad3 activation in the transforming growth factor beta signaling pathway. Mol. Cell Biol., 21 (15), 5132-41 (2001). (Pubitemid 32656409)
94. X. Guo, A. Ramirez, D. S. Waddell, Z. Li, X. Liu and X. F. Wang: Axin and GSK3-beta control Smad3 protein stability and modulate TGF- signaling. Genes Dev, 22 (1), 106-20 (2008).
95. S. Miura, T. Takeshita, H. Asao, Y. Kimura, K. Murata, Y. Sasaki, J. I. Hanai, H. Beppu, T. Tsukazaki, J. L. Wrana, K. Miyazono and K. Sugamura: Hgs (Hrs), a FYVE domain protein, is involved in Smad signaling through cooperation with SARA. Mol. Cell Biol., 20 (24), 9346-55 (2000). (Pubitemid 32246119)
96. H. Lin, S. Bergmann and P. P. Pandolfi: Cytoplasmic PML function in TGF-beta signalling. Nature, 431, 205- 211 (2004). (Pubitemid 39243475)
97. V. Prokova, S. Mavridou, P. Papakosta and D. Kardassis: Characterization of a novel transcriptionally active domain in the transforming growth factor betaregulated Smad3 protein. Nucleic Acids Res, 33 (12), 3708- 21 (2005). (Pubitemid 41418540)
98. P. ten Dijke and C. S. Hill: New insights into TGFbeta- Smad signalling. Trends Biochem Sci, 29 (5), 265-73 (2004).
99. G. Wang, J. Long, I. Matsuura, D. He and F. Liu: The Smad3 linker region contains a transcriptional activation domain. Biochem J, 386 (Pt 1), 29-34 (2005). (Pubitemid 40289221)
100. Q. Cui, S. K. Lim, B. Zhao and F. M. Hoffmann: Selective inhibition of TGF-beta responsive genes by Smad-interacting peptide aptamers from FoxH1, Lef1 and CBP. Oncogene, 24 (24), 3864-74 (2005). (Pubitemid 40896398)
101. Y. Higaki, D. Schullery, Y. Kawata, M. Shnyreva, C. K. Abrass and K. Bomsztyk: Synergistic activation of the rat laminin γ1 chain promoter by the gut-enriched Kruppellike factor (GKLF/KLF4) and Sp1. Nucl Acids Res, 30, 2270-79 (2002). (Pubitemid 34618978)
102. Y. Kawata, H. Suzuki, Y. Higaki, O. Denisenko, D. Schullery, C. Abrass and K. Bomsztyk: bcn-1 Element-dependent activation of the laminin gamma 1 chain gene by the cooperative action of transcription factor E3 (TFE3) and Smad proteins. J Biol Chem, 277 (13), 11375-84 (2002). (Pubitemid 34952904)
103. K. Bomsztyk, O. Denisenko and J. Ostrowski: hnRNP K: one protein multiple processes. Bioessays, 26 (6), 629- 38 (2004). (Pubitemid 38758340)
104. W. Zhang, J. Ou, Y. Inagaki, P. Greenwel and F. Ramirez: Synergistic cooperation between Sp1 and Smad3/Smad4 mediates TGFbeta1 stimulation of alpha2 (I) collagen (COL1A2) transcription. J Biol Chem, 275, 39237-39245 (2000). (Pubitemid 32058942)
105. A.-C. Poncelet and H. W. Schnaper Sp1 and Smad proteins cooperate to mediate TGF-beta1-induced alpha2(I) collagen expression in human glomerular mesangial cells. J. Biol Chem., 276, 6983-92 (2001).
106. J. Long, G. Wang, I. Matsuura, D. He and F. Liu: Activation of Smad transcriptional activity by protein inhibitor of activated STAT3 (PIAS3). Proc Natl Acad Sci U S A, 101 (1), 99-104 (2004). (Pubitemid 38084210)
107. R. A. Randall, M. Howell, C. S. Page, A. Daly, P. A. Bates and C. S. Hill: Recognition of phosphorylated- Smad2-containing complexes by a novel Smad interaction motif. Mol Cell Biol, 24 (3), 1106-21 (2004). (Pubitemid 38112174)
108. K. P. Sarker, H. Kataoka, A. Chan, S. J. Netherton, I. Pot, M. A. Huynh, X. Feng, A. Bonni, K. Riabowol and S. Bonni: ING2 as a novel mediator of TGF-beta -dependent responses in epithelial cells. J Biol Chem (2008).
109. C. Collart, J. E. Remacle, S. Barabino, L. A. van Grunsven, L. Nelles, A. Schellens, T. Van de Putte, S. Pype, D. Huylebroeck and K. Verschueren: Smicl is a novel Smad interacting protein and cleavage and polyadenylation specificity factor associated protein. Genes Cells, 10 (9), 897-906 (2005). (Pubitemid 41246018)
110. F. Afzal, J. Pratap, K. Ito, Y. Ito, J. L. Stein, A. J. van Wijnen, G. S. Stein, J. B. Lian and A. Javed: Smad function and intranuclear targeting share a Runx2 motif required for osteogenic lineage induction and BMP2 responsive transcription. J Cell Physiol, 204 (1), 63-72 (2005). (Pubitemid 40776807)
111. A. K. Ghosh, Y. Mori, E. Dowling and J. Varga: Trichostatin A blocks TGF-beta-induced collagen gene expression in skin fibroblasts: involvement of Sp1. Biochem Biophys Res Commun, 354 (2), 420-6 (2007). (Pubitemid 46161342)
112. I. Imoto, A. Pimkhaokham, T. Watanabe, F. Saito-Ohara, E. Soeda and J. Inazawa: Amplification and overexpression of TGIF2, a novel homeobox gene of the TALE superclass, in ovarian cancer cell lines. Biochem Biophys Res Commun, 276 (1), 264-70 (2000).
113. D. Wotton, R. S. Lo, S. Lee and J. Massague: A Smad transcriptional corepressor. Cell, 97 (1), 29-39 (1999). (Pubitemid 29165887)
114. K. Luo, S. L. Stroschein, W. Wang, D. Chen, E. Martens, S. Zhou and Q. Zhou: The Ski oncoprotein interacts with the Smad proteins to repress TGFbeta signaling. Genes Dev, 13 (17), 2196-206. (1999). (Pubitemid 29426725)
115. S. Akiyoshi, H. Inoue, J. Hanai, K. Kusanagi, N. Nemoto, K. Miyazono and M. Kawabata: c-Ski acts as a transcriptional co-repressor in transforming growth factorbeta signaling through interaction with smads. J Biol Chem, 274 (49), 35269-77 (1999). (Pubitemid 129509586)
116. M. Takeda, M. Mizuide, M. Oka, T. Watabe, H. Inoue, H. Suzuki, T. Fujita, T. Imamura, K. Miyazono and K. Miyazawa: Interaction with Smad4 is indispensable for suppression of BMP signaling by c-Ski. Mol Biol Cell, 15 (3), 963-72 (2004). (Pubitemid 38316207)
117. C. Prunier, M. Pessah, N. Ferrand, S. R. Seo, P. Howe and A. Atfi: The oncoprotein Ski acts as an antagonist of transforming growth factor-beta signaling by suppressing Smad2 phosphorylation. J Biol Chem, 278 (28), 26249-57 (2003). (Pubitemid 36835394)
118. M. Mizuide, T. Hara, T. Furuya, M. Takeda, K. Kusanagi, Y. Inada, M. Mori, T. Imamura, K. Miyazawa and K. Miyazono: Two short segments of Smad3 are important for specific interaction of Smad3 with c-Ski and SnoN. J Biol Chem, 278 (1), 531-6 (2003). (Pubitemid 36043606)
119. T. Shinagawa, H. D. Dong, M. Xu, T. Maekawa and S. Ishii: The sno gene, which encodes a component of the histone deacetylase complex, acts as a tumor suppressor in mice. Embo J, 19 (10), 2280-91 (2000). (Pubitemid 30259009)
120. S. L. Stroschein, W. Wang, S. Zhou, Q. Zhou and K. Luo: Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein. Science, 286 (5440), 771-4. (1999).
121. K. Izutsu, M. Kurokawa, Y. Imai, K. Maki, K. Mitani and H. Hirai: The corepressor CtBP interacts with Evi-1 to repress transforming growth factor beta signaling. Blood, 97 (9), 2815-22 (2001).
122. C. Dai and Y. Liu: Hepatocyte growth factor antagonizes the profibrotic action of TGF-beta1 in mesangial cells by stabilizing Smad transcriptional corepressor TGIF. J Am Soc Nephrol, 15 (6), 1402-12 (2004). (Pubitemid 38679665)
123. Y. Liu: Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am J Physiol Renal Physiol, 287 (1), F7-16 (2004).
124. W. Wang, X. R. Huang, A. G. Li, F. Liu, J. H. Li, L. D. Truong, X. J. Wang and H. Y. Lan: Signaling mechanism of TGF-beta1 in prevention of renal inflammation: role of Smad7. J Am Soc Nephrol, 16 (5), 1371-83 (2005). (Pubitemid 41716521)
125. N. A. Wahab, B. S. Weston and R. M. Mason: Modulation of the TGFbeta/Smad signaling pathway in mesangial cells by CTGF/CCN2. Exp Cell Res, 307 (2), 305-14 (2005). (Pubitemid 40803489)
126. D. Javelaud and A. Mauviel: Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis. Oncogene, 24 (37), 5742-50 (2005). (Pubitemid 43086134)
127. J. J. Mulsow, R. W. Watson, J. M. Fitzpatrick and P. R. O'Connell: Transforming growth factor-beta promotes pro-fibrotic behavior by serosal fibroblasts via PKC and ERK1/2 mitogen activated protein kinase cell signaling. Ann Surg, 242 (6), 880-7, discussion 887-9 (2005).
128. S. I. Kim, J. H. Kwak, M. Zachariah, Y. He, L. Wang and M. E. Choi: TGF-beta-activated kinase 1 and TAK1- binding protein 1 cooperate to mediate TGF-beta1-induced MKK3-p38 MAPK activation and stimulation of type I collagen. Am J Physiol Renal Physiol, 292 (5), F1471-8 (2007). (Pubitemid 46701875)
129. L. Wang, R. Ma, R. A. Flavell and M. E. Choi: Requirement of mitogen-activated protein kinase kinase 3 (MKK3) for activation of p38alpha and p38delta MAPK isoforms by TGF-beta 1 in murine mesangial cells. J Biol Chem, 277 (49), 47257-62 (2002). (Pubitemid 36159236)
130. I. Niculescu-Duvaz, M. K. Phanish, P. Colville-Nash and M. E. Dockrell: The TGFbeta1-induced fibronectin in human renal proximal tubular epithelial cells is p38 MAP kinase dependent and Smad independent. Nephron Exp Nephrol, 105 (4), e108-16 (2007). (Pubitemid 46496818)
131. L. Wang, J. H. Kwak, S. I. Kim, Y. He and M. E. Choi: Transforming growth factor-beta1 stimulates vascular endothelial growth factor 164 via mitogenactivated protein kinase kinase 3-p38alpha and p38delta mitogen-activated protein kinase-dependent pathway in murine mesangial cells. J Biol Chem, 279 (32), 33213-9 (2004). (Pubitemid 39062967)
132. H. M. Kocher, J. Moorhead, C. C. Sharpe, M. E. Dockrell, M. Al-Nawab and B. M. Hendry: Expression of Ras GTPases in normal kidney and in glomerulonephritis. Nephrol Dial Transplant, 18 (11), 2284-92 (2003). (Pubitemid 37336815)
133. C. E. Runyan, H. W. Schnaper and A.-C. Poncelet: Smad3 and PKCdelta mediate TGF-beta1-induced type I collagen expression in human mesangial cells. Am J Physiol Renal Physiol, 285, F413-F422 (2003). (Pubitemid 37010851)
134. C. E. Runyan, H. W. Schnaper and A.-C. Poncelet: The PI3K-Akt pathway enhances Smad3-stimulated mesangial cell collagen I expression in response to TGFbeta1. J Biol Chem, 279, 2632-2639 (2004). (Pubitemid 38114250)
135. S. J. Wicks, S. Lui, N. Abdel-Wahab, R. M. Mason and A. Chantry: Inactivation of smad-transforming growth factor beta signaling by Ca (2+)-calmodulin-dependent protein kinase II. Mol Cell Biol, 20 (21), 8103-11. (2000).
136. N. Lloberas, J. M. Cruzado, M. Franquesa, I. Herrero-Fresneda, J. Torras, G. Alperovich, I. Rama, A. Vidal and J. M. Grinyo: Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol, 17 (5), 1395-404 (2006). (Pubitemid 43673420)
137. R. Ortega-Velazquez, M. Gonzalez-Rubio, M. P. Ruiz-Torres, M. L. Diez-Marques, M. C. Iglesias, M. Rodriguez-Puyol and D. Rodriguez-Puyol: Collagen I upregulates extracellular matrix gene expression and secretion of TGF-beta 1 by cultured human mesangial cells. Am J Physiol Cell Physiol, 286 (6), C1335-43 (2004). (Pubitemid 38649983)
138. C. D. Roskelley and M. J. Bissell: Dynamic reciprocity revisited: a continuous, bidirectional flow of information between cells and the extracellular matrix regulates mammary epithelial cell function. Biochem Cell Biol, 73 (7-8), 391-7 (1995).
139. K. Hahm, M. E. Lukashev, Y. Luo, W. J. Yang, B. M. Dolinski, P. H. Weinreb, K. J. Simon, L. Chun Wang, D. R. Leone, R. R. Lobb, D. J. McCrann, N. E. Allaire, G. S. Horan, A. Fogo, R. Kalluri, C. F. Shield, 3rd, D. Sheppard, H. A. Gardner and S. M. Violette: Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse. Am J Pathol, 170 (1), 110-25 (2007). (Pubitemid 47342405)
140. M. Zeisberg, J. Hanai, H. Sugimoto, T. Mammoto, D. Charytan, F. Strutz and R. Kalluri: BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transitionand reverses chronic renal injury. Nat Med, 9 (7), 964-8 (2003). (Pubitemid 36889942)
141. S. N. Wang, J. Lapage and R. Hirschberg: Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy. J Am Soc Nephrol, 12 (11), 2392-9 (2001). (Pubitemid 33021116)
142. S. Wang, M. de Caestecker, J. Kopp, G. Mitu, J. Lapage and R. Hirschberg: Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J Am Soc Nephrol, 17 (9), 2504-12 (2006). (Pubitemid 44300966)
143. S. Wang and R. Hirschberg: BMP7 antagonizes TGFbeta -dependent fibrogenesis in mesangial cells. Am J Physiol Renal Physiol, 284 (5), F1006-13 (2003). (Pubitemid 36443585)
144. S. Wang and R. Hirschberg: Bone morphogenetic protein-7 signals opposing transforming growth factor beta in mesangial cells. J Biol Chem, 279 (22), 23200-6 (2004). (Pubitemid 38685626)
145. X. L. Zhang, W. Selbi, C. de la Motte, V. Hascall and A. O. Phillips: Bone morphogenic protein-7 inhibits monocyte-stimulated TGF-beta1 generation in renal proximal tubular epithelial cells. J Am Soc Nephrol, 16 (1), 79-89 (2005). (Pubitemid 43073159)
146. J. Yang and Y. Liu: Delayed administration of hepatocyte growth factor reduces renal fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol, 284 (2), F349-57 (2003). (Pubitemid 36114697)
147. J. Yang, C. Dai and Y. Liu: A novel mechanism by which hepatocyte growth factor blocks tubular epithelial to mesenchymal transition. J Am Soc Nephrol, 16 (1), 68-78 (2005). (Pubitemid 43073158)
148. B. L. Riser, P. Cortes, C. Heilig, J. Grondin, S. Ladson-Wofford, D. Patterson and R. G. Narins: Cyclic stretching force selectively up-regulates transforming growth factor-β isoforms in cultured rat mesangial cells. Am J Pathol, 148, 1915-1923 (1996). (Pubitemid 26170516)
149. J. C. Krepinsky, Y. Li, D. Tang, L. Liu, J. Scholey and A. J. Ingram: Stretch-induced Raf-1 activation in mesangial cells requires actin cytoskeletal integrity. Cell Signal, 17 (3), 311-20 (2005). (Pubitemid 39574692)
150. J. C. Krepinsky, Y. Li, Y. Chang, L. Liu, F. Peng, D. Wu, D. Tang, J. Scholey and A. J. Ingram: Akt mediates mechanical strain-induced collagen production by mesangial cells. J Am Soc Nephrol, 16 (6), 1661-72 (2005). (Pubitemid 41716472)
151. M. Isono, M. C. Cruz, S. Chen, S. W. Hong and F. N. Ziyadeh: Extracellular signal-regulated kinase mediates stimulation of TGF-beta1 and matrix by high glucose in mesangial cells. J Am Soc Nephrol, 11, 2222-2230 (2000).
152. R. V. Durvasula, A. T. Petermann, K. Hiromura, M. Blonski, J. Pippin, P. Mundel, R. Pichler, S. Griffin, W. G. Couser and S. J. Shankland: Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int, 65 (1), 30-9 (2004). (Pubitemid 38037489)
153. G. Wolf, F. N. Ziyadeh, G. Zahner and R. A. Stahl: Angiotensin II-stimulated expression of transforming growth factor beta in renal proximal tubular cells: attenuation after stable transfection with the c-mas oncogene. Kidney Int, 48 (6), 1818-27 (1995).
154. P. P. Sayeski and K. E. Bernstein: Signal transduction mechanisms of the angiotensin II type AT (1)-receptor: looking beyond the heterotrimeric G protein paradigm. J Renin Angiotensin Aldosterone Syst, 2 (1), 4-10 (2001). (Pubitemid 33687412)
155. J. Chen, J. K. Chen, E. G. Neilson and R. C. Harris: Role of EGF receptor activation in angiotensin II-induced renal epithelial cell hypertrophy. J Am Soc Nephrol, 17 (6), 1615-23 (2006). (Pubitemid 43794664)
156. W. Wang, X. R. Huang, E. Canlas, K. Oka, L. D. Truong, C. Deng, N. A. Bhowmick, W. Ju, E. P. Bottinger and H. Y. Lan: Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circ Res, 98 (8), 1032-9 (2006).
157. Y. Ito, J. Aten, R. J. Bende, B. S. Oemar, T. J. Rabelink, J. J. Weening and R. Goldschmeding: Expression of connective tissue growth factor in human renal fibrosis. Kidney Int, 53 (4), 853-61 (1998). (Pubitemid 28155657)
158. S. Wang, M. Denichilo, C. Brubaker and R. Hirschberg: Connective tissue growth factor in tubulointerstitial injury of diabetic nephropathy. Kidney Int, 60 (1), 96-105 (2001). (Pubitemid 32587544)
159. H. Yokoi, M. Mukoyama, A. Sugawara, K. Mori, T. Nagae, H. Makino, T. Suganami, K. Yahata, Y. Fujinaga, I. Tanaka and K. Nakao: Role of connective tissue growth factor in fibronectin expression and tubulointerstitial fibrosis. Am J Physiol Renal Physiol, 282 (5), F933-42 (2002). (Pubitemid 34654499)
160. W. Qi, S. Twigg, X. Chen, T. S. Polhill, P. Poronnik, R. E. Gilbert and C. A. Pollock: Integrated actions of transforming growth factor-beta1 and connective tissue growth factor in renal fibrosis. Am J Physiol Renal Physiol, 288 (4), F800-9 (2005). (Pubitemid 40381749)
161. M. K. Phanish, N. A. Wahab, B. M. Hendry and M. E. Dockrell: TGF-beta1-induced connective tissue growth factor (CCN2) expression in human renal proximal tubule epithelial cells requires Ras/MEK/ERK and Smad signalling. Nephron Exp Nephrol, 100 (4), e156-65 (2005). (Pubitemid 40910994)
162. Y. Li, X. Wen, B. C. Spataro, K. Hu, C. Dai and Y. Liu: hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferatoractivated receptor-gamma agonists. J Am Soc Nephrol, 17 (1), 54-65 (2006).
163. X. Wen, Y. Li, K. Hu, C. Dai and Y. Liu: Hepatocyte growth factor receptor signaling mediates the anti-fibrotic action of 9-cis-retinoic acid in glomerular mesangial cells. Am J Pathol, 167 (4), 947-57 (2005). (Pubitemid 41416248)
164. J. Blush, J. Lei, W. Ju, S. Silbiger, J. Pullman and J. Neugarten: Estradiol reverses renal injury in Alb/TGFbeta1 transgenic mice. Kidney Int, 66 (6), 2148-54 (2004). (Pubitemid 41115278)
165. J. Neugarten, I. Medve, J. Lei and S. R. Silbiger: Estradiol suppresses mesangial cell type I collagen synthesis via activation of the MAP kinase cascade. Am J Physiol, 277, F875-F881 (1999). (Pubitemid 30046062)
166. M. Zdunek, S. Silbiger, J. Lei and J. Neugarten: Protein kinase CK2 mediates TGF-beta1-stimulated type IV collagen gene transcription and its reversal by estradiol. Kidney Int., 60, 2097-2108 (2001). (Pubitemid 33070453)
167. L. Barisoni, H. W. Schnaper and J. B. Kopp: A proposed taxonomy for the podocytopathies: a reassessment of the primary nephrotic diseases. Clin J Am Soc Nephrol, 2 (3), 529-42 (2007).
168. M. R. Pollak: Inherited podocytopathies: FSGS and nephrotic syndrome from a genetic viewpoint. J Am Soc Nephrol, 13 (12), 3016-23 (2002). (Pubitemid 35386922)
169. M. Schiffer, M. Bitzer, I. S. Roberts, J. B. Kopp, P. ten Dijke, P. Mundel and E. P. Bottinger: Apoptosis in podocytes induced by TGF-beta and Smad7. J. Clin. Invest., 108, 807-816 (2001). (Pubitemid 32880291)
170. R. C. Wiggins: The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int, 71 (12), 1205-14 (2007). (Pubitemid 46884251)
171. J. Yoo, M. Ghiassi, L. Jirmanova, A. G. Balliet, B. Hoffman, A. J. Fornace, Jr., D. A. Liebermann, E. P. Bottinger and A. B. Roberts: Transforming growth factor-beta-induced apoptosis is mediated by Smaddependent expression of GADD45b through p38 activation. J Biol Chem, 278 (44), 43001-7 (2003). (Pubitemid 37345913)
172. T. Khera, J. Martin, S. Riley, R. Steadman and A. O. Phillips: Glucose enhances mesangial cell apoptosis. Lab Invest, 86 (6), 566-77 (2006). (Pubitemid 43780438)
173. S. J. Shankland, F. Eitner, K. L. Hudkins, T. Goodpaster, V. D'Agati and C. E. Alpers: Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and maturation. Kidney Int, 58 (2), 674-83 (2000). (Pubitemid 30620016)
174. N. Wahab, D. Cox, A. Witherden and R. M. Mason: Connective tissue growth factor (CTGF) promotes activated mesangial cell survival via upregulation of mitogen-activated protein kinase phosphatase-1 (MKP-1). Biochem J, 406 (1), 131-8 (2007). (Pubitemid 47264743)
175. N. Abdel-Wahab, B. S. Weston, T. Roberts and R. M. Mason: Connective tissue growth factor and regulation of the mesangial cell cycle: role in cellular hypertrophy. J Am Soc Nephrol, 13 (10), 2437-45 (2002).
176. T. Wada, J. W. Pippin, Y. Terada and S. J. Shankland: The cyclin-dependent kinase inhibitor p21 is required for TGF-beta1-induced podocyte apoptosis. Kidney Int, 68 (4), 1618-29 (2005). (Pubitemid 43169907)
177. G. Wolf, A. Schanze, R. A. Stahl, S. J. Shankland and K. Amann: p27 (Kip1) Knockout mice are protected from diabetic nephropathy: evidence for p27 (Kip1) haplotype insufficiency. Kidney Int, 68 (4), 1583-9 (2005). (Pubitemid 43169903)
178. J. Yang and Y. Liu: Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am. J. Pathol., 159, 1465-1475 (2002).
179. A. A. Eddy: Molecular basis of renal fibrosis. Pediatr Nephrol, 15 (3-4), 290-301 (2000).
180. F. Strutz, M. Zeisberg, F. N. Ziyadeh, C. Q. Yang, R. Kalluri, G. A. Muller and E. G. Neilson: Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int, 61 (5), 1714-28 (2002). (Pubitemid 34437925)
181. H. Okada, T. M. Danoff, R. Kalluri and E. G. Neilson: Early role of Fsp1 in epithelial-mesenchymal transformation. Am J Physiol, 273 (4 Pt 2), F563-74 (1997).
182. C. Prunier and P. H. Howe: Disabled-2 (Dab2) is required for transforming growth factor beta-induced epithelial to mesenchymal transition (EMT). J Biol Chem, 280 (17), 17540-8 (2005). (Pubitemid 41389228)
183. B. C. Liu, M. X. Li, J. D. Zhang, X. C. Liu, X. L. Zhang and A. O. Phillips: Inhibition of integrin-linked kinase via a siRNA expression plasmid attenuates connective tissue growth factor-induced human proximal tubular epithelial cells to mesenchymal transition. Am J Nephrol, 28 (1), 143-51 (2008). (Pubitemid 350126505)
184. J. Zavadil, L. Cermak, N. Soto-Nieves and E. P. Bottinger: Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. Embo J, 23 (5), 1155-65 (2004). (Pubitemid 38436879)
185. L. Ivanova, M. J. Butt and D. G. Matsell: Mesenchymal transition in kidney collecting duct epithelial cells. Am J Physiol Renal Physiol (2008).
186. Y. Li, Y. S. Kang, C. Dai, L. P. Kiss, X. Wen and Y. Liu: Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. Am J Pathol, 172 (2), 299-308 (2008). (Pubitemid 351282018)
187. R. J. Johnson, J. Floege, A. Yoshimura, H. Iida, W. G. Couser and C. E. Alpers: The activated mesangial cell: a glomerular "myofibroblast"? J Am Soc Nephrol, 2 (10 Suppl), S190-7 (1992).
188. G. Bassez, O. J. Camand, V. Cacheux, A. Kobetz, F. Dastot-Le Moal, D. Marchant, M. Catala, M. Abitbol and M. Goossens: Pleiotropic and diverse expression of ZFHX1B gene transcripts during mouse and human development supports the various clinical manifestations ofthe "Mowat-Wilson" syndrome. Neurobiol Dis, 15 (2), 240- 50 (2004). (Pubitemid 38296755)
189. A. Miquelajauregui, T. Van de Putte, A. Polyakov, A. Nityanandam, S. Boppana, E. Seuntjens, A. Karabinos, Y. Higashi, D. Huylebroeck and V. Tarabykin: Smadinteracting protein-1 (Zfhx1b) acts upstream of Wnt signaling in the mouse hippocampus and controls its formation. Proc Natl Acad Sci U S A, 104 (31), 12919-24 (2007). (Pubitemid 47255255)
190. J. Comijn, G. Berx, P. Vermassen, K. Verschueren, L. van Grunsven, E. Bruyneel, M. Mareel, D. Huylebroeck and F. van Roy: The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell, 7 (6), 1267-78 (2001). (Pubitemid 32607360)
191. Y. Imamichi, A. Konig, T. Gress and A. Menke: Collagen type I-induced Smad-interacting protein 1 expression downregulates E-cadherin in pancreatic cancer. Oncogene, 26 (16), 2381-5 (2007). (Pubitemid 46572808)
192. J. Long, D. Zuo and M. Park: Pc2-mediated sumoylation of Smad-interacting protein 1 attenuates transcriptional repression of E-cadherin. J Biol Chem, 280 (42), 35477-89 (2005). (Pubitemid 41532738)
193. F. Dastot-Le Moal, M. Wilson, D. Mowat, N. Collot, F. Niel and M. Goossens: ZFHX1B mutations in patients with Mowat-Wilson syndrome. Hum Mutat, 28 (4), 313-21 (2007). (Pubitemid 46542917)
194. T. Shirakihara, M. Saitoh and K. Miyazono: Differential regulation of epithelial and mesenchymal markers by deltaEF1 proteins in epithelial mesenchymal transition induced by TGF-beta. Mol Biol Cell, 18 (9), 3533-44 (2007). (Pubitemid 47378691)
195. M. Kato, J. Zhang, M. Wang, L. Lanting, H. Yuan, J. J. Rossi and R. Natarajan: MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A, 104 (9), 3432-7 (2007). (Pubitemid 46364176)
196. A. Boutet, C. A. De Frutos, P. H. Maxwell, M. J. Mayol, J. Romero and M. A. Nieto: Snail activation disrupts tissue homeostasis and induces fibrosis in the adult kidney. Embo J, 25 (23), 5603-13 (2006). (Pubitemid 44847200)
197. J. Yoshino, T. Monkawa, M. Tsuji, M. Inukai, H. Itoh and M. Hayashi: Snail1 is involved in the renal epithelialmesenchymal transition. Biochem Biophys Res Commun, 362 (1), 63-8 (2007). (Pubitemid 47296293)
198. T. P. de Boer, T. A. van Veen, M. F. Bierhuizen, B. Kok, M. B. Rook, K. J. Boonen, M. A. Vos, P. A. Doevendans, J. M. de Bakker and M. A. van der Heyden: Connexin43 repression following epithelium-tomesenchyme transition in embryonal carcinoma cells requires Snail1 transcription factor. Differentiation, 75 (3), 208-18 (2007). (Pubitemid 46426620)
199. X. Chen, A. Zankl, F. Niroomand, Z. Liu, H. A. Katus, L. Jahn and C. Tiefenbacher: Upregulation of ID protein by growth and differentiation factor 5 (GDF5) through a smad-dependent and MAPK-independent pathway in HUVSMC. J Mol Cell Cardiol, 41 (1), 26-33 (2006). (Pubitemid 43946963)
200. Y. Kang, C. R. Chen and J. Massague: A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol Cell, 11 (4), 915-26 (2003). (Pubitemid 36566314)
201. M. Kowanetz, U. Valcourt, R. Bergstrom, C. H. Heldin and A. Moustakas: Id2 and Id3 define the potency of cell proliferation and differentiation responses to transforming growth factor beta and bone morphogenetic protein. Mol Cell Biol, 24 (10), 4241-54 (2004). (Pubitemid 41070996)